M Rosa Dalmau Llorca1,2,3, Carina Aguilar Martín3,4,5, Noèlia Carrasco-Querol3,4, Zojaina Hernández Rojas1,2,3, Emma Forcadell Drago1,3, Dolores Rodríguez Cumplido3,6, Josep M Pepió Vilaubí1,3, Elisabet Castro Blanco2,3, Alessandra Q Gonçalves3,4,7, José Fernández-Sáez2,3,4. 1. Equip d'Atenció Primària Terres de l'Ebre, Institut Català de la Salut, Tortosa, 43500 Tarragona, Spain. 2. Grupo GAVINA, Campus Terres de l'Ebre, Universitat Rovira i Virgili, Tortosa, 43500 Tarragona, Spain. 3. GAVINA Research Group, Tortosa, 43500 Tarragona, Spain. 4. Unitat de Suport a la Recerca Terres de l'Ebre, Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Tortosa, 43500 Tarragona, Spain. 5. Unitat d'Avaluació, Direcció d'Atenció Primària Terres de l'Ebre, Institut Català de la Salut, Tortosa, 43500 Tarragona, Spain. 6. Hospital Universitari de Bellvitge, Institut Català de la Salut, 08907 Barcelona, Spain. 7. Unitat Docent de Medicina de Familia i Comunitària, Tortosa-Terres de l'Ebre, Institut Català de la Salut, Tortosa, 43500 Tarragona, Spain.
Abstract
Background: Oral anticoagulants (OAs) are the treatment to prevent stroke in atrial fibrillation (AF). Anticoagulant treatment choice in non-valvular atrial fibrillation (NVAF) must be individualized, taking current guidelines into account. Adequacy of anticoagulant therapy under the current criteria for NVAF in real-world primary care is presented. Methods: Cross-sectional study, with real-world data from patients treated in primary care (PC). Data were obtained from the System for the Improvement of Research in Primary Care (SIDIAP) database, covering 60,978 NVAF-anticoagulated patients from 287 PC centers in 2018. Results: In total, 41,430 (68%) were treated with vitamin K antagonists (VKAs) and 19,548 (32%) NVAF with direct-acting oral anticoagulants (DOACs). Inadequate prescription was estimated to be 36.0% and 67.6%, respectively. Most DOAC inadequacy (77.3%) was due to it being prescribed as a first-line anticoagulant when there was no history of thromboembolic events or intracranial hemorrhage (ICH). A total of 22.1% had missing estimated glomerular filtration rate (eGFR) values. Common causes of inadequate VKA prescription were poor control of time in therapeutic range (TTR) (98.8%) and ICH (2.2%). Conclusions: Poor adequacy to current criteria was observed, being inadequacy higher in DOACs than in VKAs. TTR and GFR should be routinely calculated in electronic health records (EHR) to facilitate decision-making and patient safety.
Background: Oral anticoagulants (OAs) are the treatment to prevent stroke in atrial fibrillation (AF). Anticoagulant treatment choice in non-valvular atrial fibrillation (NVAF) must be individualized, taking current guidelines into account. Adequacy of anticoagulant therapy under the current criteria for NVAF in real-world primary care is presented. Methods: Cross-sectional study, with real-world data from patients treated in primary care (PC). Data were obtained from the System for the Improvement of Research in Primary Care (SIDIAP) database, covering 60,978 NVAF-anticoagulated patients from 287 PC centers in 2018. Results: In total, 41,430 (68%) were treated with vitamin K antagonists (VKAs) and 19,548 (32%) NVAF with direct-acting oral anticoagulants (DOACs). Inadequate prescription was estimated to be 36.0% and 67.6%, respectively. Most DOAC inadequacy (77.3%) was due to it being prescribed as a first-line anticoagulant when there was no history of thromboembolic events or intracranial hemorrhage (ICH). A total of 22.1% had missing estimated glomerular filtration rate (eGFR) values. Common causes of inadequate VKA prescription were poor control of time in therapeutic range (TTR) (98.8%) and ICH (2.2%). Conclusions: Poor adequacy to current criteria was observed, being inadequacy higher in DOACs than in VKAs. TTR and GFR should be routinely calculated in electronic health records (EHR) to facilitate decision-making and patient safety.
Entities:
Keywords:
atrial fibrillation; direct oral anticoagulants; renal function; time in therapeutic range; vitamin K antagonists
Authors: Bonaventura Bolíbar; Francesc Fina Avilés; Rosa Morros; Maria del Mar Garcia-Gil; Eduard Hermosilla; Rafael Ramos; Magdalena Rosell; Jordi Rodríguez; Manuel Medina; Sebastian Calero; Daniel Prieto-Alhambra Journal: Med Clin (Barc) Date: 2012-03-22 Impact factor: 1.725
Authors: Doug Coyle; Kathryn Coyle; Chris Cameron; Karen Lee; Shannon Kelly; Sabine Steiner; George A Wells Journal: Value Health Date: 2013-04-23 Impact factor: 5.725
Authors: Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin Journal: N Engl J Med Date: 2011-08-27 Impact factor: 91.245
Authors: François Laliberté; Michel Cloutier; Winnie W Nelson; Craig I Coleman; Dominic Pilon; William H Olson; C V Damaraju; Jeffrey R Schein; Patrick Lefebvre Journal: Curr Med Res Opin Date: 2014-04-02 Impact factor: 2.580
Authors: Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Luisa Ibáñez; Mònica Sabaté; Xavier Vidal; Elena Ballarin; Marietta Rottenkolber; Sven Schmiedl; Andreas Heeke; Consuelo Huerta; Elisa Martin Merino; Dolores Montero; Luz María Leon-Muñoz; Christiane Gasse; Nicholas Moore; Cécile Droz; Régis Lassalle; Mia Aakjaer; Morten Andersen; Marie Louise De Bruin; Rolf Groenwold; Hendrika A van den Ham; Patrick Souverein; Olaf Klungel; Helga Gardarsdottir Journal: Br J Clin Pharmacol Date: 2019-09-04 Impact factor: 4.335
Authors: M Rosa Dalmau Llorca; Carina Aguilar Martín; Noèlia Carrasco-Querol; Zojaina Hernández Rojas; Emma Forcadell Drago; Dolores Rodríguez Cumplido; Elisabet Castro Blanco; Alessandra Queiroga Gonçalves; José Fernández-Sáez Journal: Int J Environ Res Public Health Date: 2021-05-26 Impact factor: 3.390